• GARP promotes the proliferation and therapeutic resistance of bone sarcoma cancer cells through the activation of TGF-beta 

      Carrillo-Gálvez, Ana Belén; Quintero, Juan Esteban; Rodríguez, René; Menéndez, Sofía T.; González, M. Victoria; Blanco-Lorenzo, Verónica; Allonca, Eva; Farias, Virgínea de Araújo; González-Correa, Juan Elías; Erill-Sagalés, Nadina; Martínez-Zubiaurre, Iñigo; Hellevik, Turid; Sánchez-Hernández, Sabina; Muñoz, Pilar; Zurita, Federico; Martín, Francisco; Rodríguez-Manzaneque, Juan Carlos; Anderson, Per (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-11-17)
      Sarcomas are mesenchymal cancers with poor prognosis, representing about 20% of all solid malignancies in children, adolescents, and young adults. Radio- and chemoresistance are common features of sarcomas warranting the search for novel prognostic and predictive markers. GARP/LRRC32 is a TGF-β-activating protein that promotes immune escape and dissemination in various cancers. However, if GARP ...